UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer

Ramus, SJ; Song, H; Dicks, E; Tyrer, JP; Rosenthal, AN; Intermaggio, MP; Fraser, L; ... Gayther, SA; + view all (2015) Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. JNCI: Journal of The National Cancer Institute , 107 (11) 10.1093/jnci/djv214. Green open access

[thumbnail of Fraser_BRIP1 manuscript.pdf]
Preview
Text
Fraser_BRIP1 manuscript.pdf - Accepted Version

Download (483kB) | Preview
[thumbnail of Fraser_BRIP1-Supplementary Tables.pdf]
Preview
Text
Fraser_BRIP1-Supplementary Tables.pdf - Accepted Version

Download (547kB) | Preview
[thumbnail of Fraser_BRIP1 Paper Figure 1.pdf]
Preview
Text
Fraser_BRIP1 Paper Figure 1.pdf - Accepted Version

Download (81kB) | Preview
[thumbnail of Fraser_BRIP1-Tables.pdf]
Preview
Text
Fraser_BRIP1-Tables.pdf - Accepted Version

Download (513kB) | Preview

Abstract

BACKGROUND: Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, responsible for 13 000 deaths per year in the United States. Risk prediction based on identifying germline mutations in ovarian cancer susceptibility genes could have a clinically significant impact on reducing disease mortality. METHODS: Next generation sequencing was used to identify germline mutations in the coding regions of four candidate susceptibility genes—BRIP1, BARD1, PALB2 and NBN—in 3236 invasive EOC case patients and 3431 control patients of European origin, and in 2000 unaffected high-risk women from a clinical screening trial of ovarian cancer (UKFOCSS). For each gene, we estimated the prevalence and EOC risks and evaluated associations between germline variant status and clinical and epidemiological risk factor information. All statistical tests were two-sided. RESULTS: We found an increased frequency of deleterious mutations in BRIP1 in case patients (0.9%) and in the UKFOCSS participants (0.6%) compared with control patients (0.09%) (P = 1 x 10–4 and 8 x 10–4, respectively), but no differences for BARD1 (P = .39), NBN1 (P = .61), or PALB2 (P = .08). There was also a difference in the frequency of rare missense variants in BRIP1 between case patients and control patients (P = 5.5 x 10–4). The relative risks associated with BRIP1 mutations were 11.22 for invasive EOC (95% confidence interval [CI] = 3.22 to 34.10, P = 1 x 10–4) and 14.09 for high-grade serous disease (95% CI = 4.04 to 45.02, P = 2 x 10–5). Segregation analysis in families estimated the average relative risks in BRIP1 mutation carriers compared with the general population to be 3.41 (95% CI = 2.12 to 5.54, P = 7×10–7). CONCLUSIONS: Deleterious germline mutations in BRIP1 are associated with a moderate increase in EOC risk. These data have clinical implications for risk prediction and prevention approaches for ovarian cancer and emphasize the critical need for risk estimates based on very large sample sizes before genes of moderate penetrance have clinical utility in cancer prevention.

Type: Article
Title: Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Open access status: An open access version is available from UCL Discovery
DOI: 10.1093/jnci/djv214
Publisher version: https://doi.org/10.1093/jnci/djv214
Additional information: © The Author 2015. Published by Oxford University Press. All rights reserved.
Keywords: Mutation, genes, germ-line mutation, ovarian cancer, bard1 gene, palb2 gene
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health > Womens Cancer
URI: https://discovery.ucl.ac.uk/id/eprint/1488626
Downloads since deposit
961Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item